Oncotelic Initiates Phase 2 Trial Evaluating OT-101 in Combination with KEYTRUDA® for Mesothelioma
December 01, 2021 09:01 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology,...
Monthly information on share capital and company voting rights
November 08, 2021 16:30 ET
|
Cellectis Inc.
NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
CoImmune Announces Collaboration with Top US Cancer Center to Accelerate Development of CAR-CIK Therapies to Treat Solid Tumors
October 18, 2021 08:00 ET
|
CoIMMUNE
DURHAM, N.C., Oct. 18, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today...
Monthly information on share capital and company voting rights
October 11, 2021 16:30 ET
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal...
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 03, 2021 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick...
Tasrif Pharmaceutical Announces Grant of U.S. Patent for Humanized Monoclonal Antibodies against the Poliovirus Receptor
August 25, 2021 12:00 ET
|
Tasrif Pharmaceutical, LLC
BOSTON, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Tasrif Pharmaceutical announces the grant of a US Patent related to its proprietary humanized monoclonal antibodies against the poliovirus receptor (a.k.a....
The CRISPR based therapeutics market is projected to be worth around USD 2.2 billion by 2030, growing at an annualized rate of 129.2%, claims Roots Analysis
August 03, 2021 08:31 ET
|
Roots Analysis
London, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “CRISPR based Therapeutics Market, 2021-2030” report to its list of offerings. With over 115 candidates under...
Monthly information on share capital and company voting rights
August 02, 2021 16:30 ET
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 ...
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 26, 2021 17:25 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced an equity...
Monthly information on share capital and company voting rights
July 12, 2021 16:30 ET
|
Cellectis Inc.
NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...